Institute of Functional Interfaces, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany.
GE Healthcare, Uppsala, Sweden.
N Biotechnol. 2018 May 25;42:48-55. doi: 10.1016/j.nbt.2018.02.007. Epub 2018 Feb 21.
Monoclonal antibodies are a dominant component of today's biopharmaceutical market and are typically purified by classical platform processes. However, high costs and rising demands are drivers for the development of new, efficient and flexible integrated purification processes. Currently, high-gradient magnetic separation as a direct capturing tool for protein purification suffers from the lack of suitable GMP-compliant separation equipment for industrial scale. As a solution for this bottleneck, we present a purification process for a monoclonal antibody directly from CHO cell culture by use of protein A-functionalized magnetic particles together with the first pilot-scale GMP-compliant 'rotor-stator' high-gradient magnetic separator. Five consecutive purification cycles were performed, achieving consistent yields of over 85% and purities of over 95%. Stable cell viabilities during the magnetic separation process enable integration of the device as an in situ product removal tool. A comparison with state-of-the-art protein A column-based purification processes reveals a 3-times higher process productivity per mL of applied resin and demonstrates the great potential of magnetic separation in downstream processing.
单克隆抗体是当今生物制药市场的主要组成部分,通常通过经典的平台工艺进行纯化。然而,高成本和不断增长的需求是开发新的、高效和灵活的集成纯化工艺的驱动因素。目前,高梯度磁分离作为一种用于蛋白质纯化的直接捕获工具,由于缺乏适用于工业规模的符合 GMP 标准的分离设备,因此受到限制。针对这一瓶颈问题,我们提出了一种从 CHO 细胞培养物中直接纯化单克隆抗体的方法,使用了蛋白 A 功能化的磁性颗粒和第一台符合 GMP 标准的“转子-定子”高梯度磁分离器。进行了五次连续的纯化循环,获得了超过 85%的一致收率和超过 95%的纯度。在磁分离过程中稳定的细胞活力使得该设备能够作为原位产物去除工具进行集成。与最先进的基于蛋白 A 柱的纯化工艺相比,该方法每毫升应用树脂的生产效率提高了 3 倍,证明了磁分离在下游加工中的巨大潜力。